MTNB Stock Overview
A clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Matinas BioPharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.52 |
| 52 Week High | US$18.49 |
| 52 Week Low | US$0.48 |
| Beta | 1.54 |
| 1 Month Change | -10.31% |
| 3 Month Change | 1.96% |
| 1 Year Change | -97.19% |
| 3 Year Change | -98.75% |
| 5 Year Change | -98.00% |
| Change since IPO | -99.20% |
Recent News & Updates
Shareholder Returns
| MTNB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.3% | -5.9% | -3.4% |
| 1Y | -97.2% | -11.9% | 6.1% |
Return vs Industry: MTNB underperformed the US Biotechs industry which returned -8.9% over the past year.
Return vs Market: MTNB underperformed the US Market which returned 5.8% over the past year.
Price Volatility
| MTNB volatility | |
|---|---|
| MTNB Average Weekly Movement | 18.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: MTNB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MTNB's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 32 | Jerry Jabbour | www.matinasbiopharma.com |
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.
Matinas BioPharma Holdings, Inc. Fundamentals Summary
| MTNB fundamental statistics | |
|---|---|
| Market cap | US$2.75m |
| Earnings (TTM) | -US$21.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs MTNB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MTNB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$12.72m |
| Gross Profit | -US$12.72m |
| Other Expenses | US$8.41m |
| Earnings | -US$21.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MTNB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/31 11:30 |
| End of Day Share Price | 2025/03/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Matinas BioPharma Holdings, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Jason McCarthy | Maxim Group |
| Yasmeen Rahimi | Piper Sandler Companies |